- The acquisition confirms the Group’s commitment to expanding within the European area.
- Following Portugal, the UK represents a new high-potential market.
- The closing is expected in the coming autumn.
Monza, June 30, 2025 – The Sapio Group has signed an agreement to acquire Baywater Healthcare UK Limited from the French group Bastide. Baywater Healthcare operates in the UK in the field of home oxygen therapy and home respiratory care.
This is a strategically significant acquisition, as Baywater Healthcare is a market leader in the UK, serving over 60,000 patients with a market share exceeding 50%. The company generates approximately €60 million in annual revenues and employs around 500 people.
“We are very pleased that the Bastide Group has chosen to enter into an agreement with our company,” commented Maurizio Colombo, Vice President of Sapio, “as it attests to the strength of our acquisition and integration plan compared to other qualified competitors. It also marks an important acceleration of our international development strategy, which began many years ago. Our approach has always prioritized the quality of patient care, and we immediately found strong alignment with the Baywater management team. The UK is a growing market, and in the future we will be able to support patients with additional conditions we already serve in other countries. As a family-owned company, on behalf of all Sapio shareholders, we are pleased to welcome Baywater’s employees to our Group, pending approval from UK authorities, and we look forward to working together.”
“We are extremely satisfied to have reached the agreement for the acquisition of Baywater Healthcare,” added Mario Paterlini, CEO of the Sapio Group, “first and foremost because it represents a major step forward in the development of our ‘Inspire’ plan, through which we aim to become one of the leading independent players in homecare services across Europe. Baywater Healthcare’s leadership position offers a unique opportunity for Sapio to operate in the UK. The company has achieved excellent results in recent years, thanks to a highly experienced and professional management team, and it will integrate seamlessly into Sapio’s strategy and values. The addition of Baywater Healthcare also confirms Sapio’s commitment to investing in high-growth potential countries like the UK and to continuing our international expansion by exploring all available market opportunities.”
The completion of the transaction is subject to customary closing conditions, and Sapio expects to finalize the acquisition—supported by Goodwin Procter (UK) LLP as legal advisor and EightAdvisory as financial and tax advisor—during the third quarter of 2025.